Thermo Fisher Scientific has made a groundbreaking leap in precision medicine with the introduction of the Orbitrap Astral mass spectrometer. This cutting-edge technology ushers in a new era of proteomics and clinical research, fundamentally transforming our approach to precision medicine. Bridging
In recent years, the pharmaceutical and biotechnology sectors have experienced a dynamic landscape in mergers and acquisitions (M&A). From major multimillion-dollar deals to strategic acquisitions targeting high-demand therapeutic areas, the industry has witnessed fluctuations driven by various
AbbVie, renowned for its portfolio of groundbreaking treatments, has achieved a major milestone with the FDA's approval of Vyalev, a novel combination therapy aimed at providing extended movement control for patients with advanced Parkinson’s disease. The approval represents more than just a t
Monoclonal antibodies (mAbs) have become a cornerstone of modern medicine, offering targeted therapies for a range of diseases, including various cancers, autoimmune disorders, and infectious diseases. However, developing these complex molecules is resource-intensive, requiring significant time and
The biopharmaceutical industry is undergoing a significant transformation, driven by the need for speed, safety, and cost-efficiency in therapeutic production. The advent of new modalities like cell and gene therapies has added layers of complexity to the already intricate production pipelines. As
The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
The biopharmaceutical manufacturing sector stands at the brink of a revolution, driven by the relentless pursuit of speed, safety, and scalability. The emergence of new therapeutic modalities, coupled with the increasing demand for rapid and cost-effective production solutions, has necessitated a
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent
In an ambitious endeavor to revolutionize cancer treatment, Boehringer Ingelheim and Circle Pharma have entered into a research partnership and license agreement aimed at developing a first-in-class cyclin inhibitor. This groundbreaking collaboration is set to provide novel treatment options for
The landscape of cancer treatment is ever-evolving, with new therapies continually pushing the boundaries of what is possible. Kiromic BioPharma's latest advancement, Deltacel, an allogeneic gamma delta T-cell (GDT) therapy, is showing significant promise in the treatment of advanced non-small
